4//SEC Filing
BIND Therapeutics, Inc 4
Accession 0001181431-14-002553
CIK 0001385228operating
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 6:30 PM ET
Size
16.2 KB
Accession
0001181431-14-002553
Insider Transaction Report
Form 4
Berk Gregory
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2014-01-13+4,967→ 4,967 totalExercise: $2.78→ Common Stock (4,967 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-01-13−4,453→ 3,180 totalExercise: $2.52→ Common Stock (4,453 underlying) - Award
Stock Option (Right to Buy)
2013-10-24+4,967→ 9,934 totalExercise: $2.78→ Common Stock (4,967 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-01-13−64,189→ 47,391 totalExercise: $2.52→ Common Stock (64,189 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-01-13−4,967→ 0 totalExercise: $2.78→ Common Stock (4,967 underlying)
Footnotes (4)
- [F1]Effective January 14, 2014, the reporting person resigned his position as Chief Medical Officer of the Issuer and entered into an agreement to provide certain consulting services to the Issuer (the "Consulting Agreement").
- [F2]On April 23, 2013 the reporting person was granted an option for the right to purchase 14,901 shares of common stock with an expiration date of April 22, 2023 and vesting subject to the satisfaction of certain performance conditions during the period of the option. The performance conditions with respect to one-third of the options were met on October 24, 2013, resulting in vesting of the option as to 4,967 shares. The performance conditions with respect to an additional one-third of the options were met on January 13, 2014, resulting in vesting of the option as to 4,967 shares. The 4,967 shares remaining subject to the option grant and performance conditions were forfeited and cancelled as of January 13, 2014 by mutual agreement of the reporting person and the Issuer.
- [F3]As reported on the reporting person's Form 3 filed on September 19, 2013, on October 16, 2012, the reporting person was granted an option for the right to purchase 7,633 shares of common stock at an exercise price of $2.52 with an expiration date of October 15, 2022. Beginning on May 12, 2012, the option vests 25% after one year and in 36 equal monthly installments thereafter. By mutual agreement on January 13, 2014, the reporting person and the Issuer agreed that 3,180 shares subject to the option had vested under their terms and 4,453 shares subject to the option were forfeited and cancelled as consideration for the Consulting Agreement.
- [F4]As reported on the reporting person's Form 3 filed on September 19, 2013, on June 12, 2012, the reporting person was granted an option for the right to purchase 111,580 shares of common stock at an exercise price of $2.52 with an expiration date of June 11, 2022. Beginning on May 12, 2012, the option vests 25% after one year and in 36 equal monthly installments thereafter. By mutual agreement on January 13, 2014, the reporting person and the Issuer agreed that: (i) 46,491 shares subject to the option had vested under their terms, (ii) 64,189 shares subject to the option were forfeited and cancelled as consideration for the Consulting Agreement and (iii) the remaining 900 unvested shares subject to the option shall be retained and vest at the rate of 150 shares per month for six successive months pursuant to the original vesting schedule.
Documents
Issuer
BIND Therapeutics, Inc
CIK 0001385228
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001385228
Filing Metadata
- Form type
- 4
- Filed
- Jan 14, 7:00 PM ET
- Accepted
- Jan 15, 6:30 PM ET
- Size
- 16.2 KB